Contraindicated (1)bortezomib will improve the amount or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or reasonable CYP2C19 inhibitors may well maximize mavacamten systemic publicity, causing coronary heart failure on account of systolic dysfunction. chloramphenicol will raise the level or result of bortezomib by influencing hepatic... https://josephq888doz1.illawiki.com/user